KDR and neoplasm: Assumedly, apatinib highly selectively competes with intracellular vascular endothelial growth factor receptor 2, and binds to it, thereby inhibiting tumor angiogenesis and reducing tumor blood supply, oxygen supply, and other nutrients supply to tumor growth [17–19].